Backgrounds/Aims: Hepatic resection has only guaranteed long-term survival in patients with colorectal liver metastasis (CRLM) even in the era of effective chemotherapy. The definite role of neoadjuvant chemotherapy (NCT) is to improve outcomes of unresectable CRLMs, but it its role has not been defined for initially resectable CRLMs (IR-CRLMs). Methods: We reviewed the medical records of 226 patients, who had been diagnosed and treated for IR-CRLM between 2003 and 2008; the patients had the following pathologies: 10% had more than 4 nodules, 11% had tumors larger than 5 cm, and 61% had synchronous CRMLs. Among these patients, 20 patients (Group Y) were treated with NCT, and 206 (Group N) did not receive NCT according to their physician's preference. The median follow-up time was 34.1 months. Results: The initial surgical plans were changed after NCT to further resection in 20% and to limited resection in 10% of 20 patients. Complication rates of Groups Y (30%) were indifferent from Group N (23%) (p=0.233), but intraoperative transfusions were more frequent in Group N (15%) than in Group Y (5%) (p=0.006). There was one case of hospital mortality (0.44%). Disease-free survival rates in Groups Y and N were 23% and 39%, respectively, and patient survival rates were 42% and 66% (p＞0.05). By multivariate analysis, old age (≥60 years), differentiation of primary tumor (poorly/mucinous), resection margin involvement, and no adjuvant chemotherapy were associated with poor patient survival; the number of CRLMs (≥4) was associated with poor disease-free survival. Conclusions: NCT had neither a positive impact nor a negative impact on survival, even with intraoperative transfusion, as observed on operative outcomes for patients with IR-CRLM. Further study is required to elucidate the role of NCT for treatment of patient with IR-CRLMs. 
INTRODUCTION
Hepatic resection has only guaranteed long-term survival in patients with colorectal liver metastases (CRLM). [1] [2] [3] Recent improvements in perioperative care and in surgical techniques of hepatic resection have produced excellent surgical outcomes and have increased the surgical options available to patients with advanced metastatic tumors. 1, [3] [4] [5] [6] [7] [8] [9] For this reason, the patients with technically resectable metastases due to CRLM actually had undergone hepatic resection in the large volume centers of hepatic surgery.
"Technically resectable" CRLM was defined as the possibility of an oncologically radical operation and the possibility of preserving adequate liver function as introduced.
Adequate liver function after hepatic resection included various meanings; in our center, major hepatectomy was decided according to the reference values as follows: a remnant liver volume via a CT volumetry ≥25% of the total liver volume and the parabolic pattern of oral glucose intolerance test or ＜15% of indocyanine green (ICG) 15-minutes retention test (ICG R15). By contrast, the total number, the size, their unilateral or bilateral presentation, and hilar node metastasis were not considered exclusion criteria. Moreover, as the outcomes of hepatic resection in recent retrospective reviews were excellent, 1, 3 these selection criteria for hepatic resection have been ac-cepted as the standard in patients with CRLM in our center since 2003. However, some of the patients, who underwent hepatic resection according to these extended criteria, had shown rapid tumor progression after hepatic resection in spite of effective adjuvant chemotherapy. [10] [11] [12] [13] Since 2005, neoadjuvant chemotherapy (NCT) has been prescribed for patients with initially resectable CRLMs (IR-CRLMs) with the expectation that it would prevent early recurrence after hepatic resection, resulting in a survival benefit. For, NCT has been given according to the oncologist's preference, although the role of NCT has typically been mainly down staging or debulking for curative surgery for initially unresectable CRLMs. However, the role of NCT has not been elucidated in patients with IR-CRLMs.
On a retrospective basis, we evaluated the survival outcome of patients with IR-CRLMs treated with NCT and analyzed the factors affecting prognosis after hepatic resection for IR-CRLMs.
METHODS
A total of 226 patients with CRLMs underwent hepatic resection at Seoul National University Hospital from 
NCT for patients with IR-CRLMs

Surgical procedures
A standardized hepatic resection was performed under anesthesia in conditions of low central venous blood pressure before parenchymal transection without the Pringle maneuver. Intraoperative ultrasound was carried out to obtain an adequate resection margin and to confirm vascular structures on CT scans and/or MRI. [14] [15] [16] The number, size, and the resection margin of CRLMs were determined by a pathologist.
Resections were defined on the basis of the Brisbane description of hepatic anatomy. 17 Resections less than a segmentectomy were defined as wedge resections. Major hepatectomy was defined as resection of more than 2 consecutive segments except left lateral sectionectomy or a remnant liver volume less than 30% of the total liver volume. Minor hepatectomy was defined as a resection other than major hepatectomy. Statistical analysis SPSS software, version 17.0 was used for data analysis.
End point of the study
Univariate analysis was performed using the chi-squared test or Student's t-test. The Kaplan-Meier method and the log-rank test were used to evaluate patient survival for various prognostic factors. The Cox proportional hazard regression model was used to assess the independent prognostic influence of various factors on patient survival. All variables that were significantly associated with survival on the univariate level were included. Significance levels were set at p＜0.05. 
RESULTS
Patient profiles
Survival analysis
Median follow-up was 34.1 months (range, 0-88 months) for all patients and 31.4 months for survivors.
The overall survival rate was 62.2 months (Fig. 1A) . The patient survival rate was not different between Groups Y and N (42.0% vs. 65.7%, p=0.056) (Fig. 1B) . By univariate analysis, age (≥60 years), liver metastasis onset (synchronous), lymph node involvement of primary tumor, differentiation of primary tumor (poor/mucinous), extrahepatic lesion, number of metastases (≥4), distribution of liver metastasis (bilobar distribution), resection margin involvement, intraoperative blood loss (≥ 1,000 ml), intraoperative transfusion, and no adjuvant chemotherapy were associated with poor patient survival (Table 4) . Otherwise, NCT and diameter of the largest tumor of ≥5 cm had no marked impact on patient survival.
Multivariate analysis revealed that age (≥60 years), differentiation of primary tumor (poor/mucinous), resection margin involvement, and no adjuvant chemotherapy were independent prognostic factors of poor patient survival of IR-CRLMs (Fig. 1C-F) .
Recurrence patterns and disease-free survival
The median disease-free survival, as measured from time of hepatic resection, was 37.1 months (range, 0-86 months, Fig. 2A ). The overall disease-free survival rate was 23.0% and 38.8% in Groups Y and N, respectively (p=0.201, Fig. 2B ). The disease recurred in 130 patients (57.5%). Of these, 86 patients (66.2%) had their initial recurrence within the first year, 34 (26.2%) in the second year, and 10 (7.6%) after the second year. Thirteen patients (9.2%) underwent repeat hepatic resection of their first recurrence, and of these, 1 patient underwent hepatic resection three times. The most frequent site of initial recurrence was the liver in 54 patients (41.5%), a metastatic lymph node in 32 (24.6%), the lung in 24 (18.5%), peritoneal seeding in 7 (5.4%), and multiple recurrence sites in 13 (10%). Based on univariate analysis, all of the following were consistent with disease-free survival: lymph node involvement and stage of primary tumor, extrahepatic lesions, preoperative CEA (＞5 ng/ml), number of liver metastases p=0.004 0.3 0.14-0.69 (≥4 lesions), resection margin involvement, and resection margin ≤1 cm were associated with shorter disease-free survival (Table 5 ). On follow-up multivariate analysis, the number of liver metastases (≥4 lesions) was the only factor associated with shorter disease-free survival (Fig. 2C) .
Outcome of hepatic resection according to the NCT Median duration of NCT from diagnosis was 7.5 months (range, 1-16 months). According to the revised RECIST criteria, 4 patients (20%) showed partial response, one patient (5%) showed stable disease and 15 patients (75%) showed progressive disease in Group Y. In 15 patients with progressive disease, CRLMs were increased in both size and number in 3 patients and only in size for 12 patients during NCT. In 14 patients (70%), NCT had no clinical impact on initial surgical plans. Initial tentative surgical plans of hepatic resections were changed after NCT in 6 patients (30%) to further resection in 4 (20%) and to limited resection in 2 patients (10%).
DISCUSSION
There have been several papers focusing on the role of hepatic resection for CRLMs even in the era of effective chemotherapy. As recent advances in hepatectomy techniques have dramatically improved, operative mortality associated with hepatic resection is less than 1% in experienced surgical centers. [14] [15] [16] Moreover, the recent introduction of effective adjuvant chemotherapies and advanced diagnostic images has been widening the criteria of IR-CRLMs, although the definition has been variable in different centers.
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In spite of advanced criteria of IR-CRLMs, the 5-year survival rate was more than 50% in Group N. in the era of effective chemotherapy, the tentative surgical plan can change from major to limited resection, in order to save the liver parenchyma. [34] [35] [36] [37] [38] In this respect, all patients with IR-CRLMs could be candidates for NCT, because the chemotherapeutic agents have been more effective and some reports of initially unresectable CRLMs have supported these attempts. [39] [40] [41] In addition, it must be kept in mind that the potential hazards of chemotherapy to the liver are detrimental in proportion to the number of chemotherapy cycles. In this study, there was no benefit of NCT for the IR-CRLMs, as well as no harm. NCT was not one of the prognostic factors of DFS and patient survival rates.
According to the RECIST criteria, only 10% of patients Group N. However, age ≥60 years was the only significant risk factor of very early recurrence in Group N on multivariate analysis. Therefore, further study is required to determine which IR-CRLMs will be candidates for NCT taking survival benefit or who will respond well to NCT.
In conclusion, NCT had no positive impact on the survival outcome and no negative impact on the operative outcome in the patients with IR-CRLMs although patients
